The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study .K. M. Fleming, G. P. Aithal, T. R. Card, J. West. Alimentary Pharmacology & Therapeutics Article first published online: 4 OCT 2010 Background We lack population-based estimates of the rate of decompensation in people with compensated cirrhosis as well as…
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Gastroenterology. 2010 Aug;139(2):418-29. Epub 2010 May 7. BACKGROUND & AIMS: Eosinophilic esophagitis (EoE) is caused by immunologic reactions to ingested/inhaled allergens.
Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma.Naugler WE, Sonnenberg A. Liver Transpl. 2010 Oct;16(10):1186-94. The aim of the present study is to compare the survival rates and cost-effectiveness of different treatment strategies for small (<2 cm) hepatocellular carcinoma (HCC).
Rising trends of gastric cancer and peptic ulcer in the 19th century.Sonnenberg A, Baron JH. Aliment Pharmacol Ther. 2010 Oct;32(7):901-7. BACKGROUND: The risk of dying from gastric cancer appears to have increased among consecutive generations born during the 19th century.
High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J, Berg T; NASH Study Group. Hepatology. 2010 Aug;52(2):472-9. In uncontrolled clinical studies, ursodeoxycholic acid (UDCA) had a beneficial effect on nonalcoholic steatohepatitis (NASH). However, a large controlled trial using…
Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients Laine, L., Curtis, S. P., Cryer, B., Kaur, A. and Cannon, C. P.Al. Pharm Ther Article first published online: 23 SEP 2010 Background Nonsteroidal anti-inflammatory drugs (NSAID)-related GI effects vary based on patient characteristics.